$PMCB
PharmaCyte Biotech, Inc. Stock $pmcb

$pmcb Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000168316824008709 Filed on December 13, 2024

Income Statement

Concept	2024 Q4
Revenue	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development	$97.47K
YoY Change	18.82%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$1.106M
YoY Change	-21.53%
Operating Profit	-$1.106M
YoY Change	-21.53%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$363.5K
YoY Change	-108.66%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings	-$1.470M
YoY Change	-152.67%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.39
Diluted Earnings Per Share	-$0.39
COMMON SHARES
Basic Shares Outstanding	7.637M shares
Diluted Shares Outstanding	7.637M shares

Balance Sheet

Concept	2024 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$20.84M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$21.33M
YoY Change	-71.07%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles	$1.549M
YoY Change	-56.35%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$33.77M
YoY Change	558.28%
TOTAL ASSETS
Total Short-Term Assets	$21.33M
Total Long-Term Assets	$33.77M
Total Assets	$55.10M
YoY Change	-30.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$348.6K
YoY Change	176.31%
Accrued Expenses	$707.2K
YoY Change	-30.54%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.776M
YoY Change	-8.84%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.776M
Total Long-Term Liabilities
Total Liabilities	$11.65M
YoY Change	-44.04%
SHAREHOLDERS EQUITY
Retained Earnings	-$93.67M
YoY Change	-19.49%
Common Stock	$2.167K
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$43.45M
YoY Change
Total Liabilities & Shareholders Equity	$55.10M
YoY Change	-30.15%

Cashflow Statement

Concept	2024 Q4
OPERATING ACTIVITIES
Net Income	-$1.470M
YoY Change	-152.67%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity File Number EntityFileNumber	001-40699
	dei	Entity Registrant Name EntityRegistrantName	PHARMACYTE BIOTECH, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	62-1772151
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3960 Howard Hughes Parkway
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 500
	dei	Entity Address City Or Town EntityAddressCityOrTown	Las Vegas
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NV
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	89169
	dei	City Area Code CityAreaCode	917
	dei	Local Phone Number LocalPhoneNumber	595-2850
	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.0001 Per Share
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-1409520	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2374947	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001157075
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-10-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Trading Symbol TradingSymbol	PMCB
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20840056	usd
CY2024Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	493213	usd
CY2024Q4	us-gaap	Assets Current AssetsCurrent	21333269	usd
CY2024Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1549427	usd
CY2024Q4	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	24855000	usd
CY2024Q4	PMCB	Convertible Note Receivable Femasys ConvertibleNoteReceivableFemasys	3435000	usd
CY2024Q4	PMCB	Warrant Asset Femasys WarrantAssetFemasys	3918000	usd
CY2024Q4	us-gaap	Other Assets OtherAssets	7688	usd
CY2024Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	33765115	usd
CY2024Q4	us-gaap	Assets Assets	55098384	usd
CY2024Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	348595	usd
CY2024Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	707185	usd
CY2024Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	3720458	usd
CY2024Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4776238	usd
CY2024Q4	PMCB	Warrant Liabilities Noncurrent WarrantLiabilitiesNoncurrent	6871000	usd
CY2024Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	usd
CY2024Q4	us-gaap	Other Liabilities OtherLiabilities	6871000	usd
CY2024Q4	us-gaap	Liabilities Liabilities	11647238	usd
CY2024Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	181352842	usd
CY2024Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-93673215	usd
CY2024Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	44207381	usd
CY2024Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-23267	usd
CY2024Q4	us-gaap	Stockholders Equity StockholdersEquity	43451146	usd
CY2024Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	55098384	usd
CY2024Q4	us-gaap	Revenues Revenues	0	usd
CY2024Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.39
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--04-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2025
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2023Q4	PMCB	Series B Preferred Stock Subject To Redemption SeriesBPreferredStockSubjectToRedemption		usd
CY2024Q3	PMCB	Series B Preferred Stock Redemption SeriesBPreferredStockRedemption		usd
CY2024Q3	PMCB	Series B Preferred Stock Subject To Redemption SeriesBPreferredStockSubjectToRedemption		usd
CY2024Q4	PMCB	Fractional Shares Adjustment Value FractionalSharesAdjustmentValue		usd
CY2024Q4	PMCB	Series B Preferred Stock Redemption SeriesBPreferredStockRedemption		usd
CY2024Q4	PMCB	Series B Preferred Stock Subject To Redemption SeriesBPreferredStockSubjectToRedemption		usd
CY2024Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20840056	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	50179968	usd
	dei	Document Type DocumentType	10-Q
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	6968134	shares
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	50179968	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	259800	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	50439768	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1549427	usd
CY2024Q2	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	0	usd
CY2024Q2	PMCB	Convertible Note Receivable Femasys ConvertibleNoteReceivableFemasys	2755000	usd
CY2024Q2	PMCB	Warrant Asset Femasys WarrantAssetFemasys	5152000	usd
CY2024Q2	us-gaap	Other Assets OtherAssets	7688	usd
CY2024Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	9464115	usd
CY2024Q2	us-gaap	Assets Assets	59903883	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	389369	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	735199	usd
CY2024Q2	us-gaap	Dividends Payable Current DividendsPayableCurrent	6296696	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	7421264	usd
CY2024Q2	PMCB	Warrant Liabilities Noncurrent WarrantLiabilitiesNoncurrent	10784000	usd
CY2024Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2184000	usd
CY2024Q2	us-gaap	Other Liabilities OtherLiabilities	12968000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	20389264	usd
CY2024Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21672095	shares
CY2024Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7034259	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21672078	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8037624	shares
CY2024Q4	us-gaap	Common Stock Value CommonStockValue	2167	usd
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	2167	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	185334173	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-115625010	usd
CY2024Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	14637836	shares
CY2024Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	13634454	shares
CY2024Q2	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	42040216	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-23511	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	27647603	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	59903883	usd
CY2023Q4	us-gaap	Revenues Revenues	0	usd
	us-gaap	Revenues Revenues	0	usd
	us-gaap	Revenues Revenues	0	usd
CY2024Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	97470	usd
CY2023Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	82033	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	193486	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	186516	usd
CY2024Q4	us-gaap	Labor And Related Expense LaborAndRelatedExpense	283333	usd
CY2023Q4	us-gaap	Labor And Related Expense LaborAndRelatedExpense	229159	usd
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	672817	usd
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	469157	usd
CY2024Q4	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	138000	usd
CY2023Q4	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	306738	usd
	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	276000	usd
	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	356953	usd
CY2024Q4	us-gaap	Professional Fees ProfessionalFees	469685	usd
CY2023Q4	us-gaap	Professional Fees ProfessionalFees	519073	usd
	us-gaap	Professional Fees ProfessionalFees	980241	usd
	us-gaap	Professional Fees ProfessionalFees	844301	usd
CY2024Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	117572	usd
CY2023Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	272517	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	252403	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1627919	usd
CY2024Q4	us-gaap	Operating Expenses OperatingExpenses	1106060	usd
CY2023Q4	us-gaap	Operating Expenses OperatingExpenses	1409520	usd
	us-gaap	Operating Expenses OperatingExpenses	2374947	usd
	us-gaap	Operating Expenses OperatingExpenses	3484846	usd
CY2024Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-1106060	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3484846	usd
CY2024Q4	us-gaap	Interest Income Other InterestIncomeOther	382562	usd
CY2023Q4	us-gaap	Interest Income Other InterestIncomeOther	894181	usd
	us-gaap	Interest Income Other InterestIncomeOther	929994	usd
	us-gaap	Interest Income Other InterestIncomeOther	1770059	usd
CY2024Q4	PMCB	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	1829000	usd
CY2023Q4	PMCB	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	4075000	usd
	PMCB	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	3913000	usd
	PMCB	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	2623000	usd
CY2024Q4	PMCB	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	980000	usd
CY2023Q4	PMCB	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	-769000	usd
	PMCB	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	2184000	usd
	PMCB	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	-1299000	usd
CY2024Q4	PMCB	Change In Fair Value Of Convertible Note Receivable ChangeInFairValueOfConvertibleNoteReceivable	435000	usd
CY2023Q4	PMCB	Change In Fair Value Of Convertible Note Receivable ChangeInFairValueOfConvertibleNoteReceivable	0	usd
	PMCB	Change In Fair Value Of Convertible Note Receivable ChangeInFairValueOfConvertibleNoteReceivable	680000	usd
	PMCB	Change In Fair Value Of Convertible Note Receivable ChangeInFairValueOfConvertibleNoteReceivable	0	usd
CY2024Q4	PMCB	Change In Fair Value Of Warrant Asset Femasys ChangeInFairValueOfWarrantAssetFemasys	276000	usd
CY2023Q4	PMCB	Change In Fair Value Of Warrant Asset Femasys ChangeInFairValueOfWarrantAssetFemasys	0	usd
	PMCB	Change In Fair Value Of Warrant Asset Femasys ChangeInFairValueOfWarrantAssetFemasys	-1234000	usd
	PMCB	Change In Fair Value Of Warrant Asset Femasys ChangeInFairValueOfWarrantAssetFemasys	0	usd
CY2024Q4	PMCB	Change In Fair Value Of Investment Tnf ChangeInFairValueOfInvestmentTnf	-4265000	usd
CY2023Q4	PMCB	Change In Fair Value Of Investment Tnf ChangeInFairValueOfInvestmentTnf	0	usd
	PMCB	Change In Fair Value Of Investment Tnf ChangeInFairValueOfInvestmentTnf	-3540734	usd
	PMCB	Change In Fair Value Of Investment Tnf ChangeInFairValueOfInvestmentTnf	0	usd
CY2024Q4	PMCB	Gain On Related Party Investment Tnf GainOnRelatedPartyInvestmentTNF	0	usd
CY2023Q4	PMCB	Gain On Related Party Investment Tnf GainOnRelatedPartyInvestmentTNF	0	usd
	PMCB	Gain On Related Party Investment Tnf GainOnRelatedPartyInvestmentTNF	21395734	usd
	PMCB	Gain On Related Party Investment Tnf GainOnRelatedPartyInvestmentTNF	0	usd
CY2024Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1062	usd
CY2023Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-765	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1252	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2614	usd
CY2024Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-363500	usd
CY2023Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4199416	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	24326742	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3091445	usd
CY2024Q4	us-gaap	Net Income Loss NetIncomeLoss	-1469560	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	2789896	usd
	us-gaap	Net Income Loss NetIncomeLoss	21951795	usd
	us-gaap	Net Income Loss NetIncomeLoss	-393401	usd
CY2024Q4	us-gaap	Dividends Preferred Stock DividendsPreferredStock	443958	usd
CY2023Q4	us-gaap	Dividends Preferred Stock DividendsPreferredStock	586886	usd
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	1129759	usd
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	906735	usd
CY2024Q4	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	1045357	usd
CY2023Q4	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	4461097	usd
	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	3193404	usd
	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	7733130	usd
CY2024Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2958875	usd
CY2023Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2258087	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	17628632	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9033266	usd
CY2024Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.39
CY2024Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.39
CY2023Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2023Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.83
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.83
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.85
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.85
CY2024Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7637034	shares
CY2024Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7637034	shares
CY2023Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8765134	shares
CY2023Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8765134	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7751708	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7751708	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10683514	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10683514	shares
CY2024Q4	us-gaap	Net Income Loss NetIncomeLoss	-1469560	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	2789896	usd
	us-gaap	Net Income Loss NetIncomeLoss	21951795	usd
	us-gaap	Net Income Loss NetIncomeLoss	-393401	usd
CY2024Q4	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	61	usd
CY2023Q4	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1591	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	244	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1140	usd
CY2024Q4	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	61	usd
CY2023Q4	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1591	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	244	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1140	usd
CY2024Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1469499	usd
CY2023Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2788305	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	21952039	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-394541	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	72690344	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	70	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-319849	usd
CY2023Q3	PMCB	Preferred Stocks Accretion PreferredStocksAccretion	-3272033	usd
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	451	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-3183297	usd
CY2023Q3	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	26721897	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	39193789	usd
CY2023Q4	PMCB	Series B Preferred Stock Dividends SeriesBPreferredStockDividends	-586886	usd
CY2023Q4	PMCB	Preferred Stock Accretion Value PreferredStockAccretionValue	-4461097	usd
CY2023Q4	PMCB	Stock Repurchase During Period Value StockRepurchaseDuringPeriodValue	166603	usd
CY2023Q4	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	-1591	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	2789896	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	36767508	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	27647603	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	222677	usd
CY2024Q3	PMCB	Preferred Stock Accretion PreferredStockAccretion	-2148047	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	685801	usd
CY2024Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	183	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	23421355	usd
CY2024Q3	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	749600	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	47708370	usd
CY2024Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	119155	usd
CY2024Q4	PMCB	Preferred Stock Accretion PreferredStockAccretion	-1045357	usd
CY2024Q4	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	443958	usd
CY2024Q4	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	61	usd
CY2024Q4	us-gaap	Net Income Loss NetIncomeLoss	-1469560	usd
CY2024Q4	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	1417565	usd
CY2024Q4	us-gaap	Stockholders Equity StockholdersEquity	43451146	usd
	us-gaap	Net Income Loss NetIncomeLoss	21951795	usd
	us-gaap	Net Income Loss NetIncomeLoss	-393401	usd
	PMCB	Gain On Related Party Investments Tnf GainOnRelatedPartyInvestmentsTNF	21395734	usd
	PMCB	Gain On Related Party Investments Tnf GainOnRelatedPartyInvestmentsTNF	-0	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	341832	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	0	usd
	PMCB	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	3913000	usd
	PMCB	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	2623000	usd
	PMCB	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	2184000	usd
	PMCB	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	-1299000	usd
	PMCB	Change In Fair Value Of Convertible Notes Receivable ChangeInFairValueOfConvertibleNotesReceivable	680000	usd
	PMCB	Change In Fair Value Of Convertible Notes Receivable ChangeInFairValueOfConvertibleNotesReceivable	-0	usd
	PMCB	Change In Fair Value Of Warrant Assets Femasys ChangeInFairValueOfWarrantAssetsFemasys	-1234000	usd
	PMCB	Change In Fair Value Of Warrant Assets Femasys ChangeInFairValueOfWarrantAssetsFemasys	-0	usd
	PMCB	Change In Fair Value Of Investments Tnf ChangeInFairValueOfInvestmentsTnf	-3540734	usd
	PMCB	Change In Fair Value Of Investments Tnf ChangeInFairValueOfInvestmentsTnf	-0	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	233413	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	215508	usd
	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-40775	usd
	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-2118	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-49471	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	293632	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1428032	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1641395	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	7000000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	-0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7000000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2145708	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	26622277	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	33650075	usd
	PMCB	Redemption Of Preferred Stock RedemptionOfPreferredStock	18766416	usd
	PMCB	Redemption Of Preferred Stock RedemptionOfPreferredStock	-0	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	70	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-20912124	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7027868	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	244	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1140	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-29339912	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5385333	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	50179968	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	68039936	usd
CY2024Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20840056	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	73425269	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1600	usd
	PMCB	Noncash Derivative Liability At Initial Fair Value NoncashDerivativeLiabilityAtInitialFairValue	0	usd
	PMCB	Noncash Derivative Liability At Initial Fair Value NoncashDerivativeLiabilityAtInitialFairValue	2770000	usd
	PMCB	Noncash Warrant Liability At Initial Fair Value NoncashWarrantLiabilityAtInitialFairValue	0	usd
	PMCB	Noncash Warrant Liability At Initial Fair Value NoncashWarrantLiabilityAtInitialFairValue	14127000	usd
	PMCB	Reclassification Of Series B Convertible Preferred Stock To Current Liability ReclassificationOfSeriesBConvertiblePreferredStockToCurrentLiability	16190179	usd
	PMCB	Reclassification Of Series B Convertible Preferred Stock To Current Liability ReclassificationOfSeriesBConvertiblePreferredStockToCurrentLiability	4095271	usd
	PMCB	Accretion Of Discounts To Redemption Value Of Series B Preferred Stock AccretionOfDiscountsToRedemptionValueOfSeriesBPreferredStock	3193404	usd
	PMCB	Accretion Of Discounts To Redemption Value Of Series B Preferred Stock AccretionOfDiscountsToRedemptionValueOfSeriesBPreferredStock	7733130	usd
	PMCB	Excise Tax Accrued On Repurchase Of Common Stock ExciseTaxAccruedOnRepurchaseOfCommonStock	21457	usd
	PMCB	Excise Tax Accrued On Repurchase Of Common Stock ExciseTaxAccruedOnRepurchaseOfCommonStock	266223	usd
CY2024Q4	PMCB	Change In Fair Value Of Convertible Note Receivable ChangeInFairValueOfConvertibleNoteReceivable	435000	usd
	PMCB	Change In Fair Value Of Convertible Note Receivable ChangeInFairValueOfConvertibleNoteReceivable	680000	usd
CY2024Q4	PMCB	Change In Fair Value Of Warrant Asset Femasys ChangeInFairValueOfWarrantAssetFemasys	276000	usd
	PMCB	Change In Fair Value Of Warrant Asset Femasys ChangeInFairValueOfWarrantAssetFemasys	-1234000	usd
CY2024Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	707185	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	735199	usd
CY2024Q4	PMCB	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	1829000	usd
	PMCB	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	3913000	usd
CY2024Q4	us-gaap	Operating Lease Expense OperatingLeaseExpense	7071	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	14281	usd
CY2023Q4	us-gaap	Operating Lease Expense OperatingLeaseExpense	6631	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	15598	usd
CY2024Q4	us-gaap	Net Income Loss NetIncomeLoss	-1469560	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	2789896	usd
CY2024Q4	PMCB	Accretion Of Discounts To Redemption Of Series B Convertible Preferred Stock AccretionOfDiscountsToRedemptionOfSeriesBConvertiblePreferredStock	443958	usd
CY2023Q4	PMCB	Accretion Of Discounts To Redemption Of Series B Convertible Preferred Stock AccretionOfDiscountsToRedemptionOfSeriesBConvertiblePreferredStock	586886	usd
CY2024Q4	PMCB	Less Series B Convertible Preferred Stock Dividends LessSeriesBConvertiblePreferredStockDividends	1045357	usd
CY2023Q4	PMCB	Less Series B Convertible Preferred Stock Dividends LessSeriesBConvertiblePreferredStockDividends	4461097	usd
CY2024Q4	PMCB	Less Allocation Of Undistributed Income To Series B Convertible Preferred Stock LessAllocationOfUndistributedIncomeToSeriesBConvertiblePreferredStock	0	usd
CY2023Q4	PMCB	Less Allocation Of Undistributed Income To Series B Convertible Preferred Stock LessAllocationOfUndistributedIncomeToSeriesBConvertiblePreferredStock	0	usd
CY2024Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-2958875	usd
CY2023Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-2258087	usd
CY2024Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7637034	shares
CY2024Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7637034	shares
CY2023Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8765134	shares
CY2023Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8765134	shares
CY2024Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.39
CY2023Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2023Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
	us-gaap	Net Income Loss NetIncomeLoss	21951795	usd
	us-gaap	Net Income Loss NetIncomeLoss	-393401	usd
	PMCB	Accretion Of Discounts To Redemption Of Series B Convertible Preferred Stock AccretionOfDiscountsToRedemptionOfSeriesBConvertiblePreferredStock	3193404	usd
	PMCB	Accretion Of Discounts To Redemption Of Series B Convertible Preferred Stock AccretionOfDiscountsToRedemptionOfSeriesBConvertiblePreferredStock	7733130	usd
	PMCB	Less Series B Convertible Preferred Stock Dividends LessSeriesBConvertiblePreferredStockDividends	1129759	usd
	PMCB	Less Series B Convertible Preferred Stock Dividends LessSeriesBConvertiblePreferredStockDividends	906735	usd
	PMCB	Less Allocation Of Undistributed Income To Series B Convertible Preferred Stock LessAllocationOfUndistributedIncomeToSeriesBConvertiblePreferredStock	-3409913	usd
	PMCB	Less Allocation Of Undistributed Income To Series B Convertible Preferred Stock LessAllocationOfUndistributedIncomeToSeriesBConvertiblePreferredStock	0	usd
	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	14218719	usd
	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	-9033266	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7751708	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10683514	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.83
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.83
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.85
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.85
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19494543	shares
CY2024Q4	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19494543	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18850649	shares
CY2023Q4	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18850649	shares
CY2024Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	980000	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	2184000	usd
CY2024Q4	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Net EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet	0	usd
CY2024Q4	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	9336833	usd
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	18766416	usd
CY2024Q4	us-gaap	Accretion Expense AccretionExpense	1045357	usd
	us-gaap	Accretion Expense AccretionExpense	3193404	usd
CY2024Q4	us-gaap	Redeemable Preferred Stock Dividends RedeemablePreferredStockDividends	528500	usd
	us-gaap	Redeemable Preferred Stock Dividends RedeemablePreferredStockDividends	1062250	usd
CY2024Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	3720458	usd
CY2024Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	14637836	shares
CY2024Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	44207381	usd
CY2024Q4	PMCB	Change In Fair Value Of Investment Tnf Loss ChangeInFairValueOfInvestmentTnfLoss	4265000	usd
	PMCB	Change In Fair Value Of Investment Tnf Loss ChangeInFairValueOfInvestmentTnfLoss	3541000	usd
CY2024Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001683168-24-008709-index-headers.html	Edgar Link	pending
0001683168-24-008709-index.html	Edgar Link	pending
0001683168-24-008709.txt	Edgar Link	pending
0001683168-24-008709-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pharmacyte_ex3101.htm	Edgar Link	pending
pharmacyte_ex3102.htm	Edgar Link	pending
pharmacyte_ex3201.htm	Edgar Link	pending
pharmacyte_ex3202.htm	Edgar Link	pending
pharmacyte_i10q-103124.htm	Edgar Link	pending
pmcb-20241031.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
pmcb-20241031_cal.xml	Edgar Link	unprocessable
pmcb-20241031_def.xml	Edgar Link	unprocessable
pmcb-20241031_lab.xml	Edgar Link	unprocessable
pharmacyte_i10q-103124_htm.xml	Edgar Link	completed
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
pmcb-20241031_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PMCB
PharmaCyte Biotech, Inc. Stock $pmcb

2024 Q4 Form 10-Q Financial Statement

#000168316824008709 Filed on December 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PMCB PharmaCyte Biotech, Inc. Stock $pmcb

2024 Q4 Form 10-Q Financial Statement

#000168316824008709 Filed on December 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PMCB
PharmaCyte Biotech, Inc. Stock $pmcb